Abcellera Biologics Inc. has established a collaboration with Vertex Pharmaceuticals Inc. to research, develop, manufacture and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions.
Sail Biomedicines Inc. has established a strategic collaboration with Johnson & Johnson (J&J) to advance innovative in vivo CAR T therapies for immune-mediated diseases.
